GlaxoSmithKline plc (GSK) Receives “Neutral” Rating from JPMorgan Chase & Co.
Other research analysts have also recently issued reports about the stock. Shore Capital reiterated a hold rating on shares of GlaxoSmithKline plc in a research report on Monday, June 20th. HSBC reiterated a buy rating and set a GBX 1,970 ($25.71) price target on shares of GlaxoSmithKline plc in a research report on Monday, September 12th. Deutsche Bank AG reiterated a hold rating on shares of GlaxoSmithKline plc in a research report on Monday, June 27th. Berenberg Bank set a GBX 1,885 ($24.61) price target on shares of GlaxoSmithKline plc and gave the company a neutral rating in a research report on Tuesday, August 9th. Finally, Morgan Stanley increased their price target on shares of GlaxoSmithKline plc from GBX 1,500 ($19.58) to GBX 1,650 ($21.54) and gave the company an equal weight rating in a research report on Monday, July 11th. Three research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have given a buy rating to the stock. GlaxoSmithKline plc presently has a consensus rating of Hold and a consensus target price of GBX 1,676.44 ($21.88).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1649.00 on Thursday. GlaxoSmithKline plc has a 52 week low of GBX 1,227.50 and a 52 week high of GBX 1,716.50. The company’s market cap is GBX 80.16 billion. The firm has a 50-day moving average of GBX 1,652.88 and a 200 day moving average of GBX 1,532.04.
The company also recently declared a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, August 11th. This represents a dividend yield of 1.12%.
In other GlaxoSmithKline plc news, insider Witty,Sir Andrew P sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total transaction of £169,300 ($220,989.43). Also, insider Slaoui,Moncef purchased 28 shares of the business’s stock in a transaction on Friday, August 12th. The shares were purchased at an average price of GBX 2,208 ($28.82) per share, with a total value of £618.24 ($807.00).
About GlaxoSmithKline plc
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.